Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Medullary sponge kidney (MSK) is a birth defect of the tubules - tiny tubes inside the kidneys. In a normal kidney, urine flows through these tubules as it is being formed. In MSK, tiny sacs called cysts form in the medulla (the inner part of the kidney), creating a sponge-like appearance. The cysts keep urine from flowing freely through the tubules. MSK is present at birth but symptoms typically do not occur until adolescence or adulthood. Problems caused by MSK include blood in the urine, kidney stones, and urinary tract infections. MSK rarely leads to more serious problems, such as total kidney failure. There is no cure for this condition, so treatment is aimed at removing kidney stones and treating urinary tract infections with antibiotics.
Biomarker and diagnostic research for medullary sponge kidney has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
19 publications have been identified in PubMed for medullary sponge kidney. Research spans Review / Meta-Analysis (42%), Case Report / Case Series (21%), and Other (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 8 | 42% |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:12 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Patient case studies |
4 |
21% |
Other research | 3 | 16% |
Testing and diagnosis research | 1 | 5% |
Clinical study results | 1 | 5% |
Disease patterns and progression | 1 | 5% |
New treatment approaches | 1 | 5% |
Tournebize C (2026). [PMID: 41790480](https://pubmed.ncbi.nlm.nih.gov/41790480/). *Nephrol Dial Transplant*. [Gene Therapy / Novel Therapeutics]
Ayotunde F (2026). [PMID: 41460036](https://pubmed.ncbi.nlm.nih.gov/41460036/). *Curr Opin Nephrol Hypertens*. [Review / Meta-Analysis]
Hu X (2026). [PMID: 41816037](https://pubmed.ncbi.nlm.nih.gov/41816037/). *Quant Imaging Med Surg*. [Other]
Abasi R (2025). [PMID: 40462432](https://pubmed.ncbi.nlm.nih.gov/40462432/). *Zhongguo Dang Dai Er Ke Za Zhi*. [Review / Meta-Analysis]
Tournebize C (2025). [PMID: 40973923](https://pubmed.ncbi.nlm.nih.gov/40973923/). *J Nephrol*. [Review / Meta-Analysis]
Leventoğlu E (2025). [PMID: 41219125](https://pubmed.ncbi.nlm.nih.gov/41219125/). *Nephrology (Carlton)*. [Case Report / Case Series]
Karimzadeh-Soureshjani E (2025). [PMID: 40454330](https://pubmed.ncbi.nlm.nih.gov/40454330/). *Clin Case Rep*. [Case Report / Case Series]
Cumpanas AD (2025). [PMID: 40781702](https://pubmed.ncbi.nlm.nih.gov/40781702/). *J Endourol*. [Clinical Trial Publication]
Liu Y (2025). [PMID: 40786086](https://pubmed.ncbi.nlm.nih.gov/40786086/). *Front Med (Lausanne)*. [Diagnostic / Biomarker]
Wang F (2025). [PMID: 40826740](https://pubmed.ncbi.nlm.nih.gov/40826740/). *Medicine (Baltimore)*. [Case Report / Case Series]